Refine by
Medication For The Treatment Articles & Analysis: Older
175 news found
These unique formulations combine targeting ligands with radioisotopes, providing dual functionalities of imaging and therapeutic action. RDCs leverage medical radionuclides to integrate treatment modalities with diagnostic capabilities, augmenting personalized medicine efforts. ...
Their versatility extends to applications in cancer treatment and wound healing, making them a significant focus of biotechnological research. ...
Semaglutide Side Chain serves as a pivotal component in the synthesis of semaglutide, an innovative medication utilized in the treatment of type 2 diabetes. Huateng Pharma's unwavering dedication to excellence and innovation shines through in the meticulous development and production of these essential compounds, ensuring the highest standards of quality and ...
In the complex landscape of medical waste management, the importance of effective treatment methods cannot be overstated. Refractory materials play a crucial role in facilitating safe and efficient processes for the incineration and disposal of medical waste. In this article, we explore the significance of refractory materials in ...
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
” Lenalidomide The lenalidomide API provided by Alfa Chemistry can be used in research applications or medication production for the treatment of cancerous and anemia patients who are suffering from certain blood/bone marrow disorders. ...
This summary greatly facilitates the generation of treatment options reports and connects cancer patients and their physicians with optimal approved or investigational therapies. The platform’s portals, xINFORM for patients and xDECIDE for providers, provide scientific and medical rationales for all treatment options. The platform ...
ByxCures
Other achievements include: Continued International expansion through the signing of a memorandum of understanding (MOU) with the Kingdom of Saudi Arabia’s Ministry of Investment Long-term strategic partnership with Baxter International to help front line care providers deliver high-quality care and improve care outcomes Ongoing commercial expansion including a partnership with ...
Having clarified the Phase 3 study designs, the Company is now expanding its partnering activities on XF-73 Nasal with the aim of securing a deal in 2023. Dr Yuri Martina, Chief Medical Officer of Destiny Pharma, said: “Having finalized our Phase 3 strategy for our primary indication of SSI prevention, we are ready for the next steps in executing our well-defined and ...
Army Medical Research and Development Command, is sponsored and will be managed by the Naval Medical Research Center (NMRC) to advance medical treatments for combat wound. ...
” Other partners joining xCures in building this relationship with Aetion include AbbVie, Amgen, AstraZeneca, Bayer, Baylor College of Medicine, Brigham and Women’s Hospital and Harvard Medical School, ConcertAI, Duke-Margolis Center for Health Policy, Friends of Cancer Research, Gilead, Loopback Analytics, Pfizer, Reagan-Udall Foundation, Tempus, TriNetX, About ...
ByxCures
The study demonstrated an incremental cost-effectiveness ratio (ICER) of $17,000 per quality-adjusted life year gained, which is the academic standard for measuring how well medical treatments lengthen and/or improve patients' lives. The ICER is substantially lower than accepted willingness-to-pay thresholds in the U.S. and other healthcare systems. ...
Stuhlmiller, Asher Wasserman, Jameson Quinn, Zac Cole, Alaa Awawda, Sabrina Irizarry, Sebastian Williams, Mark Shapiro, Al Musella, Santosh Kesari “I’m proud to present these analyses of real-world data and clinical outcomes of CNS cancer patients from our observational registry,” stated xCures’ VP of Scientific and Medical Affairs Timothy J. Stuhlmiller. ...
ByxCures
Patients can share this up-to-date and accurate information with their medical providers and professionals, making it easy for them to review a patient’s cancer journey and facilitate access to promising trials or alternative treatments. ...
ByxCures
In addition, the study of protein interactions can provide new perspectives for medical diagnosis and treatment, and promote the design of new drugs and the development of biomedicine. ...
ABOUT BTL Founded in 1993, BTL has grown to become one of the world's major medical and aesthetic equipment manufacturers. With 2,800 employees located in more than 71 countries, BTL has revolutionized the way to offer the most advanced non-invasive solutions for body shaping, skin tightening & other medical aesthetic treatments, including ...
BOSTON, November 3, 2022 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. ...
ByElucid
(NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the completion of its study assessing the effect of food on absorption of its lead candidate CTx-1301, an investigational medication for the ...
“This day marks a paradigm shift in medical isotope supply wherein the international medical community can now depend on scalable, reliable, Canadian, power-reactor produced isotopes for their cancer ...
With capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms, Societal CDMO will manufacture all clinical, registration, and commercial batches of Cingulate’s lead candidate CTx-1301, an investigational medication for the treatment of Attention Deficit / ...